VRTX US92532F1003

Rapport

Vertraagde tijd Nasdaq - 22:00 05-08-2022
288.03	USD		+4.80%

05/08	VERTEX PHARMACEUTICALS : Goldman Sachs herhaalt koopadvies voor het aandeel	MM
05/08	VERTEX PHARMACEUTICALS : HC Wainwright geeft koopadvies	MM
05/08	VERTEX PHARMACEUTICALS : Een koopadvies van Barclays	MM

Nieuws

Aanbevelingen van analisten

Andere talen

Persberichten

Officiële publicaties

Sectornieuws

Analyse MarketScreener

Communiqués de presse de la société VERTEX PHARMACEUTICALS

05/08	VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..	AQ
04/08	VERTEX PHARMACEUTICALS : Reports Second Quarter 2022 Financial Results - Form 8-K	PU
04/08	VERTEX : Q2 Earnings Snapshot	AQ
04/08	Vertex Reports Second Quarter 2022 Financial Results	BU
25/07	Vertex Advances VX-548 in Acute and Neuropathic Pain	AQ
22/07	Vertex Advances VX-548 in Acute and Neuropathic Pain	BU
20/07	Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Viv..	AQ
18/07	Vertex to Announce Second Quarter 2022 Financial Results on August 4	BU
11/07	VERTEX PHARMACEUTICALS : to Acquire ViaCyte, With the Goal of Accelerating its Potentially..	PU
11/07	VERTEX PHARMACEUTICALS INC / MA : Other Events, Financial Statements and Exhibits (form 8-..	AQ
11/07	Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-88..	BU
07/07	Vertex Announces Letter of Intent With the pan-Canadian Pharmaceutical Alliance for Pub..	AQ
07/07	Teva appoints Eric Hughes as head of R&D and Chief Medical Officer	AQ
07/07	DBRS Morningstar Confirms All Ratings on Citigroup Commercial Mortgage Trust 2016-C2	AQ
06/07	Vertex Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 C..	AQ
05/07	VERTEX PHARMACEUTICALS INC / MA : Entry into a Material Definitive Agreement, Termination ..	AQ
05/07	Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial fo..	BU
04/07	Teva Announces Appointment of New Global R&D and Chief Medical Officer	AQ
13/06	Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up ..	AQ
11/06	Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up ..	BU
10/06	Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatm..	BU
08/06	Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 1..	BU
08/06	Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FD..	BU
06/06	Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes ..	BU
02/06	Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001..	BU
31/05	Vertex to Present New Data on VX-880 Clinical Trial at 82nd American Diabetes Associati..	BU
23/05	VERTEX PHARMACEUTICALS INC / MA : Other Events (form 8-K)	AQ
23/05	Catalyst Biosciences Sells Complement Portfolio for $60 Million	AQ
19/05	Vertex Pharmaceuticals - Suketu Upadhyay Elected to Vertex Board of Directors	AQ
18/05	VERTEX PHARMACEUTICALS INC / MA : Submission of Matters to a Vote of Security Holders (for..	AQ
18/05	Suketu Upadhyay Elected to Vertex Board of Directors	BU
17/05	Vertex Announces Further Expansion in the Boston Seaport at Dedication of the Jeffrey L..	BU
17/05	Vertex Announces $50 Million Commitment to Health Equity With Three Initial Grants	BU
06/05	VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..	AQ
05/05	VERTEX : Q1 Earnings Snapshot	AQ
05/05	Vertex Reports First Quarter 2022 Financial Results	BU
02/05	Vertex Provides Updates on Phase 1/2 Clinical Trial of VX-880 for the Treatment of Type..	BU
21/04	Vertex to Announce First Quarter 2022 Financial Results on May 5	BU
21/04	VRTX - Health Canada Grants Marketing Authorization for TRIKAFTA (elexacaftor/tezacafto..	AQ
20/04	Health Canada Grants Marketing Authorization for TRIKAFTA® (elexacaftor/tezacaftor/ivac..	BU
31/03	Vertex Announces Statistically Significant and Clinically Meaningful Results From Two P..	BU
28/03	Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA for Patients With Cy..	AQ
26/03	Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA® (elexacaftor/tezaca..	BU
25/03	Health Canada Grants Marketing Authorization for KALYDECO® (ivacaftor) for Patients Wit..	AQ
22/03	Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated..	BU
02/03	Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8	AQ
01/03	Vertex to Present at Cowen's 42nd Annual Health Care Conference on March 8	BU
09/02	VERTEX PHARMACEUTICALS INC / MA MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL COND..	AQ
26/01	VERTEX PHARMACEUTICALS : Q4 2021 Presentation	PU
26/01	VERTEX PHARMACEUTICALS : Reports Fourth Quarter 2021 and Full Year Financial Results - For..	PU
26/01	VERTEX : Q4 Earnings Snapshot	AQ
26/01	Vertex Reports Fourth Quarter 2021 and Full Year Financial Results	BU
18/01	Vertex to Announce Fourth Quarter 2021 Financial Results on January 26	BU
12/01	Vertex Pharmaceuticals - European Commission Approves KAFTRIO (ivacaftor/tezacaftor/ele..	AQ
11/01	European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination..	BU
04/01	Vertex to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10	BU
2021	Vertex Announces Positive Results From Phase 2 Study of VX-147 in APOL1-Mediated Focal ..	BU
2021	Vertex Announces Reimbursement Agreement in Spain for KAFTRIO (ivacaftor/tezacaftor/ele..	AQ
2021	Vertex Announces Reimbursement Agreement in Spain for KAFTRIO® (ivacaftor/tezacaftor/el..	BU
2021	Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) i..	BU
2021	VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..	AQ
2021	Q3 2021 Presentation	PU
2021	VERTEX : Q3 Earnings Snapshot	AQ
2021	Broad pipeline advancing with recent progress marked by unprecedented VX-880 clinical r..	PU
2021	Vertex Reports Third-Quarter 2021 Financial Results	BU
2021	Vertex's Supplement to a New Drug Submission for TRIKAFTA® (elexacaftor/tezacaftor/ivac..	AQ
2021	Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing T..	BU
2021	VERTEX PHARMACEUTICALS : to Announce Third-Quarter 2021 Financial Results on November 2	AQ
2021	VERTEX PHARMACEUTICALS : to Announce Third-Quarter 2021 Financial Results on November 2	BU
2021	VERTEX PHARMACEUTICALS : to Present Long-Term Data Demonstrating Significant Benefits of T..	BU
2021	VERTEX PHARMACEUTICALS : Announces Positive Day 90 Data for the First Patient in the Phase..	BU
2021	VERTEX PHARMACEUTICALS : Supplement to a New Drug Submission for KALYDECO® (ivacaftor) for..	AQ
2021	VERTEX PHARMACEUTICALS : Announces Letter of Intent With pan-Canadian Pharmaceutical Allia..	AQ
2021	VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Virtual 19th Annual Global Healt..	AQ
2021	VERTEX PHARMACEUTICALS : to Present at the Morgan Stanley Virtual 19th Annual Global Healt..	BU

1 2 3 4 5 6 7 8 9 Volgende

Officiële publicaties

06/05	SEC Filing 10Q-1
06/05	SEC Filing 8K
05/05	Press Release
05/05	1st quarter results
26/01	Press Release
26/01	Annual results

Meer Officiële publicaties

Volgende evenement op VERTEX PHARMACEUTICALS

02/11/22

Q3 2022 Cijferpublicaties (schatting)

De agenda van het bedrijf

Komende gebeurtenissen in de sector

08/08/22	BIONTECH SE : Eerste halfjaar 2022 Cijferpublicaties
27/10/22	GILEAD SCIENCES, INC. : Q3 2022 Cijferpublicaties (schatting)
03/11/22	WUXI APPTEC CO., LTD. : Q3 2022 Cijferpublicaties (schatting)
07/11/22	BIONTECH SE : Q3 2022 Cijferpublicaties

Meer evenementen

Sector

Gezondheidszorg
	Farmaceutisch en medisch onderzoek
		Biotechnologie & Medisch Onderzoek
			Biotechnologie & Medisch Onderzoek
				Biotherapeutische geneesmiddelen